New Data Highlight Artera's MMAI Consistency Across Diverse Patient Populations at ASTRO 2026

Five abstracts spanning global patient cohorts and U.S. cooperative trials reinforce the prognostic and predictive power of Artera's platform in prostate cancer

SAN FRANCISCO, September 25, 2026--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Collectively, these studies expand the evidence supporting MMAI's potential to deliver consistent, biologically meaningful insights across diverse patient populations and clinical settings. The findings carry implications for more personalized prostate cancer treatment. Details of the abstracts are below.

"We believe the future of cancer care is one where the patient's unique biology and risk increasingly inform personalized treatment decisions," said Andre Esteva, CEO and Co-founder of Artera. "These findings demonstrate the potential of Artera's platform to deliver on this vision by providing consistent, data-backed insights across diverse populations, helping clinicians better tackle some longstanding questions in medicine today."

Key Presentations at ASTRO 2026

Beyond NCCN: How a Prognostic and Predictive Multimodal AI Biomarker Drives ADT De-Escalation in Prostate Cancer

Quick Pitch: Actionable Biomarkers: Guiding Therapy Selection and De-escalation
Abstract Number: 1163
Date and Time: September 29, 5:20 PM ET, Room 205

New data from the GenesisCare-led ASTuTE Trial in Australia reveal how Artera's MMAI biomarker can help guide clinical decisions around Short-Term Androgen Deprivation Therapy (ST-ADT) for men with intermediate-risk prostate cancer. Leveraging MMAI to inform treatment discussions led many patients and clinicians to reconsider ST-ADT in both directions, avoiding the therapy when risk didn't warrant it, and pursuing it when the test indicated likely benefit. These findings continued to add to Artera's cross-continental evidence base, supporting its MMAI's potential to advance personalized treatment decisions.

Digital Pathology-Based Multimodal Artificial Intelligence Biomarker Validation in Patients with High and Very High Risk Localized Prostate Cancer from the POP-RT Trial

Oral Presentation: Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy
Abstract Number: 313
Date and Time: September 29, 4:05 PM ET; Room 210

Data demonstrate the potential of Artera's MMAI biomarker to help personalize radiation treatment for patients with high-risk localized prostate cancer. In a study of patients treated in India, whole-pelvis radiation was associated with a meaningful reduction in distant metastasis among patients with high MMAI risk, while those with intermediate MMAI risk did not derive a similar benefit. There are currently no validated biomarkers available to guide selection for whole-pelvis radiation. These findings suggest that Artera may help identify patients most likely to benefit from more extensive radiation treatment, supporting more personalized treatment decisions while potentially avoiding unnecessary radiation exposure. The study represents the first validation of Artera's MMAI in a South Asian prostate cancer population, supporting continued investigation of its potential to inform radiation treatment decisions.